Type of Study: Clinical

Sponsor and Funding: AstraZeneca

Lead Group: GOG Foundation

Collaborative Groups: LACOG and EVA Group

Primary objectives: To demonstrate the superiority of volrustomig relative to placebo by assessment of PFS, in participants with PD-L1 high expression

Principal Investigator Lead (Brazil) : Fernando Coitat Maluf

Countries: Japan, India, South Korea, Taiwan, Brazil, Canada, China, Denmark, Germany, Italy, Mexico, Norway, Peru, Poland, Spain, Turkey, United States

ClinicalTrials.gov Identifier: NCT06079671